Abstract
Advanced hepatocellular carcinoma is the third most common cause of cancer-related mortality worldwide. Systemic therapy has historically had limited efficacy; however, targeted therapies offer promise in improving patient outcomes. Recently, two pivotal phase III randomized double-blind trials of the oral multi-tyrosine kinase inhibitor sorafenib compared with placebo demonstrated a survival benefit in advanced hepatocellular carcinoma. Other targeted agents have also shown promising results in early-phase trials. This review examines the current knowledge about targeted therapies in advanced hepatocellular carcinoma and addresses some of the key issues for future research in this disease.
| Original language | English |
|---|---|
| Pages (from-to) | 81-94 |
| Number of pages | 14 |
| Journal | Asia-Pacific Journal of Oncology and Hematology |
| Volume | 2 |
| Issue number | 1 |
| Publication status | Published - Feb 2010 |
| Externally published | Yes |
Keywords
- Angiogenesis
- Growth factor
- Growth factor receptor
- Hepatocellular carcinoma
- Signal transduction pathways
- Sorafenib
- Targeted therapies
Cite this
}
Targeted therapies for the systemic treatment of advanced hepatocellular carcinoma. / Chionh, Fiona; Azad, A.; Cebon, Jonathan.
In: Asia-Pacific Journal of Oncology and Hematology, Vol. 2, No. 1, 02.2010, p. 81-94.Research output: Contribution to journal › Review Article › Research › peer-review
TY - JOUR
T1 - Targeted therapies for the systemic treatment of advanced hepatocellular carcinoma
AU - Chionh, Fiona
AU - Azad, A.
AU - Cebon, Jonathan
PY - 2010/2
Y1 - 2010/2
N2 - Advanced hepatocellular carcinoma is the third most common cause of cancer-related mortality worldwide. Systemic therapy has historically had limited efficacy; however, targeted therapies offer promise in improving patient outcomes. Recently, two pivotal phase III randomized double-blind trials of the oral multi-tyrosine kinase inhibitor sorafenib compared with placebo demonstrated a survival benefit in advanced hepatocellular carcinoma. Other targeted agents have also shown promising results in early-phase trials. This review examines the current knowledge about targeted therapies in advanced hepatocellular carcinoma and addresses some of the key issues for future research in this disease.
AB - Advanced hepatocellular carcinoma is the third most common cause of cancer-related mortality worldwide. Systemic therapy has historically had limited efficacy; however, targeted therapies offer promise in improving patient outcomes. Recently, two pivotal phase III randomized double-blind trials of the oral multi-tyrosine kinase inhibitor sorafenib compared with placebo demonstrated a survival benefit in advanced hepatocellular carcinoma. Other targeted agents have also shown promising results in early-phase trials. This review examines the current knowledge about targeted therapies in advanced hepatocellular carcinoma and addresses some of the key issues for future research in this disease.
KW - Angiogenesis
KW - Growth factor
KW - Growth factor receptor
KW - Hepatocellular carcinoma
KW - Signal transduction pathways
KW - Sorafenib
KW - Targeted therapies
UR - http://www.scopus.com/inward/record.url?scp=84868150165&partnerID=8YFLogxK
M3 - Review Article
VL - 2
SP - 81
EP - 94
JO - Asia-Pacific Journal of Oncology and Hematology
JF - Asia-Pacific Journal of Oncology and Hematology
SN - 1759-6637
IS - 1
ER -